Taconic Biosciences News & Views

Differences in the immune systems of mice and humans can lead to variations in how immuno-oncology therapies work in each, creating challenges in ensuring translatable preclinical research results. In this Q&A article in Science, Dr. Patrick Gordon, scientific program manager at Taconic Biosciences, discusses how genetically humanized mice can overcome these limitations to facilitate the development of immunotherapies. He reviews how humanized models are enabling the development...  Read More

Taconic Biosciences took the lead in bringing to market a model that's the gold standard for small molecule drug carcinogenicity testing. Our history of staying ahead of industry needs and driving innovation continues with the evolution of the rasH2 mouse model. Pharmaceutical companies are under tremendous pressure to ensure their drug candidates are safe, but they're equally strained to deliver study results faster to speed time to...  Read More

Improves Access to Critical Rodent Models for Researchers in India Rensselaer, NY — May 10, 2022 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India. India makes a significant contribution to global pharmaceutical and vaccine production, and its pharmaceutical and...  Read More

Humanized mouse models that enable more human-relevant research findings play an increasingly important role in drug discovery. In this article in Genetic Engineering & Biotechnology News, Dr. Michael Seiler, Taconic Biosciences' vice president, commercial products, discusses the heightened focus on the role of immunology in systems biology and the subsequent need for immunodeficient models that gain facets of the human immune system. Dr. Seiler reviews several such...  Read More

Taconic to add least 12 full-time positions On March 18, 2022, Taconic Biosciences broke ground on a new production facility, expanding the footprint at its 27.9-acre Cambridge City, IN, campus. Slated for completion in September, the 5,960-square-foot building increases capacity and will benefit the Cambridge City community by bringing new jobs to the region. As the new facility ramps up production, Taconic expects to hire at least...  Read More

Seamless, Comprehensive Capabilities Eliminate Barriers to Microbiome Research Rensselaer, NY — April 26, 2022 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data. The TBMI removes the...  Read More

Neurological disorders like Alzheimer's disease (AD) involve complex mechanisms that can be challenging to study. Taconic and LifeCanvas are collaborating to investigate how the disease develops and progresses, using advanced 3D histology with two Taconic mouse models used to study Alzheimer's disease. Transgenic mouse models are crucial to understanding the mechanisms of neurological disorders like Alzheimer's disease and evaluating efficacious therapies. With those goals in mind, Taconic...  Read More

Four-way distribution partnership provides quality, consistent rasH2 supply to India and China, better serving global customers Rensselaer, NY — March 21, 2022 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd. (NSI) and Nomura Jimusho. Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively. These distribution...  Read More

Stewardship Approach Safeguards All Elements of Contract Breeding Services Rensselaer, NY — February 21, 2022 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, launched Cage+, a holistic, innovative approach to murine contract breeding services. Cage+ delivers complete stewardship of projects from start to finish, allowing investigators to focus on research with confidence that animal model supply is reliable, at the highest quality,...  Read More

In a study published in the Journal of Experimental Medicine, Taconic models engrafted with patient-derived xenografts (PDX) demonstrated that mitoribosome-targeting antibiotics may have a role in treating melanoma. Despite significant advances in oncology research, tumor resistance to therapy remains a major challenge. Immune checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab exhibit a wide disparity between responders and non-responders, which has prompted investigators to explore various avenues to...  Read More